(1)Novartis Pharma AG Archives - 2021 CMSC Annual Meeting

2021 CMSC Annual Meeting

Tag: (1)Novartis Pharma AG

Poster-Disease-modifying Therapy

October 25, 2021

Dual Mode of Action of Siponimod in Secondary Progressive Multiple Sclerosis: A Hypothesis Based on the Relevance of Pharmacological Properties

Background: Siponimod, a potent and selective sphingosine 1-phosphate (S1P1,5) receptor modulator, is the first oral disease-modifying...

Read More →

MAILING ADDRESS

3 University Plaza Drive, Ste 116
Hackensack, NJ 07601

CONTACT US

(201) 487-1050
info@mscare.org

FOLLOW US

© 2021 CMSC